Crown Aesthetics Completes Rebrand to ProGen PRP Eclipse™, Combining Two Industry Leading Platelet Rich Plasma Systems

November 7, 2022 (Dallas, TX) – Crown Aesthetics ("Crown"), a division of Crown Laboratories, Inc., announced today that it has completed the rebranding of ProGen PRP Advantage, now renamed ProGen PRP Eclipse. Unifying two premium brands, ProGen PRP and Eclipse PRP, into one best-in-class product, exemplifies Crown’s unwavering commitment to providing physicians and their patients with industry-leading products and technologies. ProGen PRP Eclipse, the gold standard in Platelet-Rich Plasma, is an easy-to-use, one spin system that features 15 mL and 30 mL tubes, yielding 7-15 mL of Platelet Rich Plasma. This simple-to-use system can produce consistent results to fit all of our customers’ needs. “Crown’s commitment to best-in-class service, advanced skincare treatments, product development, and safety and efficacy is unyielding,” said Mike Zuccala, Global Vice President, Marketing for Crown Aesthetics. “By unifying our portfolio and rebranding to ProGen PRP Eclipse, we are leveraging their sizeable brand equity to best support our loyal customers.” Crown Aesthetics represents a world-class R&D organization, an expansive product portfolio following the recent acquisition of Eclipse assets, and an unwavering commitment to customer service as a significant leader in the aesthetics category. For more information about ProGen PRP Eclipse, please visit, ​​www.progenprp.com About Crown Aesthetics Crown Aesthetics, the premier medical aesthetics company, is dedicated to helping leading practices around the world grow their businesses. We do that by delivering dramatic results in rejuvenation and restoration. Our minimally-invasive innovations – SkinPen®, the first FDA-cleared microneedling device; MicroPen EVO™, platelet-rich plasma (PRP) system ProGen PRP Eclipse™, VOTESSE™, a hair health system; and the post-microneedling protocol Skinfuse®– act as "gateway" products that drive new and highly satisfied patients into practices. Based in Dallas, Texas, Crown Aesthetics sets industry standards for efficacy, safety, and innovation. As a result, our customers consistently deliver the best aesthetic care in the business. For more information, please visit www.crownaesthetics.com. About Revance Revance is a fast-growing, highly acquisitive, global aesthetics and skincare company committed to delivering innovative aesthetics and market-leading skincare solutions across every stage of life. With a differentiated portfolio and market position, Revance meets the evolving needs of patients and consumers worldwide through continued innovation and the commercialization of new products and treatments. Focused on skin science for life, Revance continues to expand its global footprint, with distribution spanning 60 countries and a significant opportunity to enter new markets. Revance’s balanced portfolio includes innovative products in the aesthetics space such as DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection, the RHA® Collection of dermal fillers by Teoxane SA, and SkinPen®, an industry-leading microneedling device. RHA® technology is proprietary to and manufactured in Switzerland by Teoxane SA, and Revance is an independent distributor of Teoxane SA to supply the RHA Collection of dermal fillers to the U.S. market. In addition, its consumer skincare portfolio includes leading brands such as PanOxyl®, Blue Lizard®, StriVectin® and BIOJUVE®. RHA® is a trademark of TEOXANE SA. Learn more at Revance.com, RevanceAesthetics.com, CrownLaboratories.com, and CrownAesthetics.com. Please see DAXXIFY® full Prescribing Information, including Boxed Warning and Medication Guide.

The release as fetched from its publisher. crownlaboratories.com ↗